Compare Logitech International SA (LOGI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Logitech International SA vs Neurocrine Biosciences Inc — how do they compare? Logitech International SA trades at $101.7 (market cap $14.65B), while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Logitech International SA pays a 1.67% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| LOGI | NBIX | |
|---|---|---|
Market Cap | $14.65B | $17.40B |
Sector | Technology | Health |
52-Week High | $126.69 | $180.55 |
52-Week Low | $85.84 | $123.10 |
Enterprise Value | $13.00B | $16.49B |
Dividend Yield | 1.67% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
